Abstract:Antonio F. Martinez-Monseny Department of Genetic and Molecular Medicine/IPER, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain Comment on: Li Q, Chen Z, Wang J, et al . Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Short Stature: A Systematic Review and Meta-Analysis. JAMA Pediatr 2023;177:1149-57. Submitted Feb 19, 2024. Accepted for publication Apr 17, 2024. Published online May 20, 2024. doi: 10.21037/tp-24-46 In the realm of contemporary medicine, the pursuit of precision and accuracy continues to drive advancements in genetic testing. For paediatric patients presenting with short stature, a condition often influenced by a myriad of genetic factors, the diagnostic landscape has undergone a transformation with the emergence of chromosomal microarray analysis (CMA) and exome sequencing (ES). This approach not only expedites the diagnostic process but also provides the opportunity to identify common genetic patterns in individuals with short stature, paving the way for more personalized and effective treatments. In this editorial commentary, I will analyze the recent paper authored by Li et al. , delving into the dynamic role of contemporary technologies in deciphering the genetic intricacies associated with short stature (1). The exploration encompasses an in-depth assessment of their diagnostic performance, challenges encountered, and the significant potential they bear for advancing patient care. This editorial commentary also aims to provide a comprehensive analysis of the comparative aspects of these two genetic testing modalities, delving into the specific advantages and limitations of each of them in the context of short stature. Short stature, defined as a height that is less than 2 standard deviations (SDs) from the mean for the respective age and gender (1,2). The aetiology of short stature is multifactorial and can result from genetic factors, hormonal factors such as growth hormone, thyroid hormones, and cortisol, and a spectrum of environmental factors (prenatal and postnatal), or a combination of both. While familial short stature and constitutional growth delay are common conditions of short stature, a subset of cases involves genetic syndromes and disorders that necessitate a comprehensive genetic evaluation for accurate diagnosis and appropriate management, particularly in cases of severe short stature with associated dysmorphic features. A significant proportion of short stature cases have an underlying genetic aetiology with more than 250 genes implicated in its pathogenesis such as SHOX , GH1 , IGF1 , IGF1R , GHR or FGFR3 , among others. Therefore, identifying the genetic basis of short stature is critical for establishing accurate diagnoses, informing prognosis, and guiding personalized management strategies (1-6). The utility of ES and CMA in the study of short stature extends beyond diagnosis. The information obtained through these advanced techniques also opens the door to potential therapeutic research. The systematic review and meta-analysis from Li et al. , involving 20 studies and a total of 2,420 patients with short stature, found an overall diagnostic yield of 27.1% for ES and 13.6% for CMA. No statistically significant difference was observed between first-tier and last-resort groups for either ES or CMA. These results provide evidence supporting the diagnostic efficacy of ES and CMA in patients with short stature, trying to serve as a valuable guidance for clinicians in recommending genetic tests. I think that while the methodology of the study regarding included and excluded articles seems appropriate, a significant limitation lies in the great heterogeneity observed within the spectrum of short stature. Most classifications of short stature consider factors to guide the diagnosis and management of patients with short stature, as they help identify patients with a higher suspicion of syndromic causes, and the diagnostic yield based on genetic testing. Some of the most frequent genetic syndromes associated with short stature are: Turner, Down, 22q11.2 deletion, Noonan, Williams, Silver-Russell and Prader-Willi syndromes, SHOX deficiency and achondroplasia, among others (2-4). CMA is a genomic technique used to detect chromosomal abnormalities and copy number variations (CNVs) across the entire genome. It has traditionally served as a screening tool in the genetic diagnostic arsenal. It excels in detecting submicroscopic chromosomal imbalances and CNV, providing a comprehensive view of the genome (7,8). CMA is the most widely used genetic screening test that rules out various genetic syndromes associated with short stature. Over time, in many types of short stature and based on associated clinical signs, it has been losing strength and giving way to ES. ES is a genomic technique of next-g -Abstract Truncated-

Genomic Basis of Syndromic Short Stature in an Algerian Patient Cohort.

Genetic Evaluation of 114 Chinese Short Stature Children in the Next Generation Era: a Single Center Study.

Genetic Findings in Short Turkish Children Born to Consanguineous Parents

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Molecular diagnosis of patients with syndromic short stature identified by trio whole-exome sequencing

Exome sequencing reveals genetic architecture in patients with isolated or syndromic short stature

Role of genetic investigation in the diagnosis of short stature in a cohort of Italian children

Clinical profiles and molecular genetic analyses of 98 Chinese children with short statures

Genetic diagnosis in Sudanese and Tunisian families with syndromic intellectual disability through exome sequencing

Clinical and genetic investigation of 14 families with various forms of short stature syndromes

Diagnostic Whole Exome Sequencing in Patients with Short Stature

Unravelling short stature in pediatrics: the crucial role of genetic perspective

Preliminary investigation into the genetic etiology of short stature in children through whole exon sequencing of the core family

Pathogenic gene screening in 91 Chinese patients with short stature of unknown etiology with a targeted next-generation sequencing panel.

Use of whole exome sequencing for identification of genetic variants related to Growth Hormone Deficiency and Short Stature: A Family-Based Study

Genetic Characterization of Short Stature Patients With Overlapping Features of Growth Hormone Insensitivity Syndromes

Utility of next generation sequencing in paediatric neurological disorders: experience from South Africa

A pilot study of gene testing of genetic bone dysplasia using targeted next-generation sequencing

Genetic studies of 77 cases of short stature with unknown etiology

Next-generation phenotyping in Nigerian children with Cornelia de Lange Syndrome

Next‐generation phenotyping in Nigerian children with Cornelia de Lange syndrome